Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNIB: nivolumab plus lenvatinib for advanced hepatocellular carcinoma
2018-001480-23Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: objective response rate. Started Oct 2018; status: completed.
02
Drugs
nivolumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-001480-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001480-23.